IL108754A0 - 2-benzyl-polycyclic guanine derivatives and process for preparing them - Google Patents

2-benzyl-polycyclic guanine derivatives and process for preparing them

Info

Publication number
IL108754A0
IL108754A0 IL10875494A IL10875494A IL108754A0 IL 108754 A0 IL108754 A0 IL 108754A0 IL 10875494 A IL10875494 A IL 10875494A IL 10875494 A IL10875494 A IL 10875494A IL 108754 A0 IL108754 A0 IL 108754A0
Authority
IL
Israel
Prior art keywords
benzyl
preparing
guanine derivatives
polycyclic guanine
polycyclic
Prior art date
Application number
IL10875494A
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of IL108754A0 publication Critical patent/IL108754A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
IL10875494A 1993-02-26 1994-02-24 2-benzyl-polycyclic guanine derivatives and process for preparing them IL108754A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2354993A 1993-02-26 1993-02-26
US2459993A 1993-02-26 1993-02-26

Publications (1)

Publication Number Publication Date
IL108754A0 true IL108754A0 (en) 1994-06-24

Family

ID=26697306

Family Applications (1)

Application Number Title Priority Date Filing Date
IL10875494A IL108754A0 (en) 1993-02-26 1994-02-24 2-benzyl-polycyclic guanine derivatives and process for preparing them

Country Status (14)

Country Link
US (1) US5939419A (xx)
EP (1) EP0686157A1 (xx)
JP (1) JPH08507068A (xx)
KR (1) KR960701058A (xx)
CN (1) CN1118600A (xx)
AU (1) AU681875B2 (xx)
CA (1) CA2156918A1 (xx)
FI (1) FI953981A (xx)
HU (1) HUT72640A (xx)
IL (1) IL108754A0 (xx)
NZ (1) NZ262797A (xx)
SG (1) SG43809A1 (xx)
TW (1) TW270118B (xx)
WO (1) WO1994019351A1 (xx)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5824683A (en) * 1995-11-28 1998-10-20 Schering Corporation 2'- 4'-halo- 1,1'-biphenyl!-4-yl!methyl!-5'-methyl-spiro cyclopentane-1,7' (8'H)- 3H! imidazo 2,1-b!purin!-4' (5'H)-ones
ZA969888B (en) * 1995-11-28 1997-05-26 Schering Corp 2'-[[4'-halo-[1,1-biphenyl]-4-yl]methyl]-5'-methyl-spiro[cyclopentane-1,7'(8'H)-[3H]imidazo[2,1-b]purin]-4'(5'H)-ones
US6410584B1 (en) 1998-01-14 2002-06-25 Cell Pathways, Inc. Method for inhibiting neoplastic cells with indole derivatives
US6200771B1 (en) 1998-10-15 2001-03-13 Cell Pathways, Inc. Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
US6133271A (en) * 1998-11-19 2000-10-17 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
US6187779B1 (en) 1998-11-20 2001-02-13 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
US6369092B1 (en) 1998-11-23 2002-04-09 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted benzimidazole derivatives
US6077842A (en) * 1998-11-24 2000-06-20 Cell Pathways, Inc. Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
US6034099A (en) * 1998-11-24 2000-03-07 Cell Pathways, Inc. Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
US6486155B1 (en) 1998-11-24 2002-11-26 Cell Pathways Inc Method of inhibiting neoplastic cells with isoquinoline derivatives
US6025394A (en) 1999-01-29 2000-02-15 Cell Pathways, Inc. Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols
US6020379A (en) * 1999-02-19 2000-02-01 Cell Pathways, Inc. Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
US6403799B1 (en) * 1999-10-21 2002-06-11 Agouron Pharmaceuticals, Inc. Methods for the preparation of intermediates in the synthesis of HIV-protease inhibitors
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
ATE395349T1 (de) * 2001-08-28 2008-05-15 Schering Corp Polycyclische guanin phosphodiesterase inhibitoren
EP1790652A1 (en) * 2001-08-28 2007-05-30 Schering Corporation Polycyclic guanine phosphodiesterase V inhibitors
WO2003020702A2 (en) * 2001-08-31 2003-03-13 The Rockefeller University Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain
US6943171B2 (en) * 2001-11-09 2005-09-13 Schering Corporation Polycyclic guanine derivative phosphodiesterase V inhibitors
EP1719772A1 (en) 2002-05-31 2006-11-08 Schering Corporation Process for preparing xanthine phosphodiesterase v inhibitors and precursors thereof
CN1860119A (zh) * 2003-07-31 2006-11-08 先灵公司 用于治疗勃起功能障碍的黄嘌呤磷酸二酯酶5抑制剂代谢物及其衍生物
KR20060101762A (ko) * 2003-11-21 2006-09-26 쉐링 코포레이션 포스포디에스테라제 ｖ 억제제 제형
SE0401653D0 (sv) * 2004-06-24 2004-06-24 Astrazeneca Ab New compounds
WO2006104870A2 (en) * 2005-03-25 2006-10-05 Schering Corporation Methods of treating benign prostatic hyperplasia or lower urinary track symptoms by using pde 5 inhibitors
WO2006133261A2 (en) * 2005-06-06 2006-12-14 Intra-Cellular Therapies, Inc. Organic compounds
EP1919287A4 (en) * 2005-08-23 2010-04-28 Intra Cellular Therapies Inc ORGANIC COMPOUNDS FOR TREATING A REDUCED DOPAMINE RECEPTOR SIGNALING ACTIVITY
WO2007073300A1 (en) 2005-12-23 2007-06-28 Astrazeneca Ab Gaba-b receptor modulators
US7745474B2 (en) 2005-12-23 2010-06-29 Astrazeneca Ab Imidazole derivatives for the treatment of gastrointestinal disorders
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
JP5453086B2 (ja) * 2006-06-06 2014-03-26 イントラ−セルラー・セラピーズ・インコーポレイテッド 有機化合物
ES2411604T3 (es) 2006-11-13 2013-07-05 Intra-Cellular Therapies, Inc. Compuestos orgánicos
US9006258B2 (en) 2006-12-05 2015-04-14 Intra-Cellular Therapies, Inc. Method of treating female sexual dysfunction with a PDE1 inhibitor
US7901872B2 (en) 2007-05-21 2011-03-08 Macronix International Co., Ltd. Exposure process and photomask set used therein
RU2010101611A (ru) * 2007-06-21 2011-07-27 Шеринг Корпорейшн (US) Полициклические производные гуанина и способы их применения
DK2240490T3 (da) 2007-12-06 2013-12-16 Takeda Pharmaceutical Organiske forbindelser
EP2240028B1 (en) * 2007-12-06 2016-07-20 Intra-Cellular Therapies, Inc. Pyrazolopyrimidine-4,6-dione derivatives and their use as pharmaceutical
WO2009144548A1 (en) * 2008-05-28 2009-12-03 Glenmark Pharmaceuticals S.A. Imidazo [2,1-b] purine derivatives as trpa1 modulators
DK2299821T3 (en) 2008-06-10 2016-02-15 Abbvie Inc Tricyclic compounds
GEP20146046B (en) 2008-12-06 2014-02-25 Intracellular Therapies Inc Organic compounds
CA2740385A1 (en) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
ES2638912T3 (es) 2008-12-06 2017-10-24 Intra-Cellular Therapies, Inc. Compuestos orgánicos
CN102238872A (zh) * 2008-12-06 2011-11-09 细胞内治疗公司 有机化合物
AU2009322905A1 (en) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
SG171776A1 (en) 2008-12-06 2011-07-28 Intra Cellular Therapies Inc Organic compounds
EP2400970A4 (en) 2009-02-25 2012-07-18 Intra Cellular Therapies Inc PDE 1 INHIBITOR FOR OPHTHALMIC DISORDERS
JP2012526810A (ja) 2009-05-13 2012-11-01 イントラ−セルラー・セラピーズ・インコーポレイテッド 有機化合物
SG178279A1 (en) 2009-08-05 2012-03-29 Intra Cellular Therapies Inc Novel regulatory proteins and inhibitors
SG181147A1 (en) 2009-12-01 2012-07-30 Abbott Lab Novel tricyclic compounds
CN108774237A (zh) 2009-12-01 2018-11-09 Abbvie 公司 新的三环化合物
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
JP5894148B2 (ja) 2010-05-31 2016-03-23 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
JP5879336B2 (ja) 2010-05-31 2016-03-08 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
WO2011153138A1 (en) 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Organic compounds
JP6051210B2 (ja) 2011-06-10 2016-12-27 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
JP6549040B2 (ja) 2013-02-17 2019-07-24 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規使用
AU2014234990B2 (en) 2013-03-15 2017-11-16 Intra-Cellular Therapies, Inc. Organic compounds
US9545406B2 (en) 2013-03-15 2017-01-17 Intra-Cellular Therapies, Inc. Method of treating a CNS injury with a PDE1 inhibitor
JP6696904B2 (ja) 2014-01-08 2020-05-20 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 製剤および医薬組成物
WO2015196186A1 (en) 2014-06-20 2015-12-23 Intra-Cellular Therapies, Inc. Organic compounds
US9546175B2 (en) 2014-08-07 2017-01-17 Intra-Cellular Therapies, Inc. Organic compounds
ES2745819T3 (es) 2014-08-07 2020-03-03 Intra Cellular Therapies Inc Derivados de imidazo[1,2-a]-pirazolo[4,3-e]-pirimidin-4-ona con actividad inhibidora de la PDE1
US10285992B2 (en) 2014-08-07 2019-05-14 Intra-Cellular Therapies, Inc. Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
ES2857567T3 (es) 2014-09-17 2021-09-29 Intra Cellular Therapies Inc Derivados de 7,8-dihidro-[2h]-imidazo-[1,2-a]pirazolo[4,3-e]pirimidin-4(5h)-ona como inhibidores de fosfodiesterasa 1 (PDE1) para tratar enfermedades, trastornos o lesiones del sistema nervioso central (SNC)
RU2702732C1 (ru) 2014-12-06 2019-10-10 Интра-Селлулар Терапиз, Инк. Органические соединения
BR112017012007B1 (pt) 2014-12-06 2022-11-01 Intra-Cellular Therapies, Inc Compostos orgânicos inibitórios de pde2, composições farmacêuticas compreendendo os ditos compostos e uso dos mesmos no tratamento de um distúrbio mediado por pde2
US11512092B2 (en) 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11773106B2 (en) 2015-10-16 2023-10-03 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
CN116284011A (zh) 2015-10-16 2023-06-23 艾伯维公司 制备咪唑并[1,2-a]吡咯并[2,3-e]吡嗪类化合物及其固态形式的方法
EP3436083A4 (en) 2016-03-28 2019-11-27 Intra-Cellular Therapies, Inc. NEW COMPOSITIONS AND METHODS
ES2906107T3 (es) 2016-09-12 2022-04-13 Intra Cellular Therapies Inc Usos novedosos
EP3562828A1 (en) 2016-12-28 2019-11-06 Dart NeuroScience LLC Substituted pyrazolopyrimidinone compounds as pde2 inhibitors
US11434247B1 (en) 2017-11-27 2022-09-06 Dart Neuroscience Llc Substituted furanopyrimidine compounds as PDE1 inhibitors
JP7401442B2 (ja) 2018-01-31 2023-12-19 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規使用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7810946L (sv) * 1978-10-20 1980-04-21 Draco Ab Metod att behandla kronisk obstruktiv luftvegssjukdom
CH643260A5 (fr) * 1980-05-02 1984-05-30 Nestle Sa 1-allyl-3-butyl-8-methylxanthine, procede de preparation et utilisation dans un medicament.
US4663446A (en) * 1983-06-27 1987-05-05 Trustees Of The Univ. Of Massachusetts N2 (phenyl substituted) deoxy guanosine containing compounds
DE3324115A1 (de) * 1983-07-05 1985-01-17 Dr. Karl Thomae Gmbh, 7950 Biberach Neue imidazole, ihre herstellung und diese verbindungen enthaltende arzneimittel
DE3347290A1 (de) * 1983-12-28 1985-07-11 Dr. Karl Thomae Gmbh, 7950 Biberach Neue 2-phenyl-imidazole, ihre herstellung und diese verbindungen enthaltende arzneimittel
DE3445299A1 (de) * 1984-12-12 1986-06-19 Dr. Karl Thomae Gmbh, 7950 Biberach Neue imidazoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE69033614T2 (de) * 1989-10-20 2001-04-19 Kyowa Hakko Kogyo Kk Kondensierte Purinderivate
NZ238609A (en) * 1990-06-21 1993-12-23 Schering Corp Polycyclic guanine derivatives; preparation, pharmaceutical compositions,
DE4022314A1 (de) * 1990-07-13 1992-01-16 Boehringer Ingelheim Kg Verfahren zur herstellung von 2-chlor-1,7-dihydropurin-6-on und verfahren zu dessen reinigung
DE4035599A1 (de) * 1990-11-06 1992-05-07 Dresden Arzneimittel Neue 5-(phenoxyalkanoylamino)-uracile, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
JP3260037B2 (ja) * 1994-06-17 2002-02-25 松下電器産業株式会社 超音波ドプラ血流計

Also Published As

Publication number Publication date
SG43809A1 (en) 1997-11-14
KR960701058A (ko) 1996-02-24
JPH08507068A (ja) 1996-07-30
WO1994019351A1 (en) 1994-09-01
NZ262797A (en) 1997-08-22
TW270118B (xx) 1996-02-11
FI953981A0 (fi) 1995-08-24
HU9502464D0 (en) 1995-10-30
AU681875B2 (en) 1997-09-11
EP0686157A1 (en) 1995-12-13
FI953981A (fi) 1995-08-24
CN1118600A (zh) 1996-03-13
HUT72640A (en) 1996-05-28
AU6268794A (en) 1994-09-14
US5939419A (en) 1999-08-17
CA2156918A1 (en) 1994-09-01

Similar Documents

Publication Publication Date Title
IL108754A0 (en) 2-benzyl-polycyclic guanine derivatives and process for preparing them
GB2293383B (en) Method of preparing 1-N-ethylgentamicin derivatives
HU9601295D0 (en) New ginkgolide derivatives and a process for preparing them
HUT64761A (en) Imidazopyridine derivatives and process for production thereof
HU9400474D0 (en) Process for producing 2-amido-4-phenyl-thiazol derivatives
ZA969220B (en) Nucleoside derivatives and process for preparing the same
GB9120628D0 (en) Pyrrolobenzoxazine derivatives and process for preparation thereof
ZA933899B (en) Thienothiazine derivatives process for their preparation and their use
HU9401331D0 (en) Substituted piperazine derivatives and process for producing them
CS199791A3 (en) Aminodiole derivatives and process for preparing thereof
IL111829A0 (en) Process for preparing imidazopyridine derivatives
OA09959A (en) Process for preparing 3-acylestratrienes and acylbenzenes
HU9400404D0 (en) Substituted imidazo-benzoxazin-1-one derivatives and process for producing them
GB2275266B (en) Process of preparing 2-methyl-3-aminobenzotrifluoride
HU9401981D0 (en) Process for preparation of chloro-methyl-pyridin derivatives
AU3710395A (en) Nucleoside derivatives and process for preparing thereof
ZA9335B (en) Difluoromethylenandrostenone derivatives and process for their preparation
ZA941280B (en) 2-Benzyl-polycyclic guanine derivatives and process for preparing them.
HUT68358A (en) New heterocycle substituted silyloxypropane derivatives and process for producing them
HU9501252D0 (en) 17-hydroxy-20-oxo-pregnane derivatives and process for producing them
HUT53892A (en) Process for producing synaminothiazolyl and synaminooxazolyl derivatives
LTIP1401A (en) Carbazolone derivatives and process for preparing the same
HUT70764A (en) 2-halogeno-methyl-saccharin derivatives and process for producing them
GB9201286D0 (en) 3-methyleneandrostane derivatives and process for their preparation
GB9224188D0 (en) Imidazolyalkyl-imidazolidinone derivatives and process for their preparation